Aiming Yu

Aiming Yu

Position Title

Department of Biochemistry and Molecular Medicine, School of Medicine

2700 Stockton Blvd. Room 2132, Sacramento, CA 95817

Research Interests

Noncoding RNA (ncRNA) epigenetics and cancer therapy

Our research is aimed at understanding the functions of noncoding RNAs in the control of cancer cellular processes including drug disposition and tumor progression and developing ncRNA-based therapies.

Grad Group Affiliations

  • Biochemistry, Molecular, Cellular and Developmental Biology
  • Integrative Genetics and Genomics
  • Pharmacology and Toxicology Graduate Group

Specialties / Focus

  • Cancer Biology
  • Gene Regulation
  • Molecular Medicine
  • RNA
  • Synthetic Biology


  • PTX 201 Principles of Pharmacology and Toxicology, Fall
  • VMB 253 Drug and Toxicant Metabolism, Winter

Professional Societies



  • 1998 Ph.D.


Zhang K, Bian J, Deng Y, Smith A, Nunez RE, Li MB, Pal U, Yu AM, Qiu W, Ealick SE, and Li CH. Lyme disease spirochete Borrelia burgdorferi does not require thiamin. Nature Microbiol. Nov. 21, 2:16213 (2016).

Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM. Development of a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model to Characterize the Thermoregulatory Effects of Serotonergic Drugs in Mice. Acta Pharm Sin B. 6(5):492-503 (2016).

Tu MJ, Pan YZ, Qiu JX, Kim E, Yu AM. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 7(29):45547-45561 (2016).

Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Genetically engineered miR-34a prodrug suppresses orthotopic osteosarcoma tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep. 6:26611 (2016).

Wang WP, Ho PY, Li MM, Chen QX, Addepalli B, Tu MJ, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, DeVere White R, Lam KS, Yu AM. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 354(2):131-141 (2015).

Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric miR-1291 biosynthesized efficiently in E. coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos. 43(7):1129-1136 (2015).

Chen QX, Wang WP, Zeng S, Uroyama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res, 43(7):3857-3869 (2015).

Jiang XL, Shen HW, and Yu AM. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology, 89:342-351 (2015).

Li MM, Wang WP, Wu WJ, Huang M, and Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 42(11):1791-1795 (2014).

Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, and Yu AM. N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291 altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis, 35(10):2264-2272 (2014).

Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 41(10):1744-1751 (2013).

See other publications on PubMed.